Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-26-279429
Filing Date
2026-06-23
Accepted
2026-06-23 16:05:45
Documents
15
Effectiveness Date
2026-06-23

Document Format Files

Seq Description Document Type Size
1 S-8 d155753ds8.htm S-8 50506
2 EX-5.1 d155753dex51.htm EX-5.1 6811
3 EX-23.2 d155753dex232.htm EX-23.2 1480
4 EX-99.1 d155753dex991.htm EX-99.1 116013
5 EX-FILING FEES d155753dexfilingfees.htm   iXBRL EX-FILING FEES 12776
6 GRAPHIC g155753page9.jpg GRAPHIC 2294
  Complete submission text file 0001193125-26-279429.txt   311844

Data Files

Seq Description Document Type Size
18 EXTRACTED XBRL INSTANCE DOCUMENT d155753dexfilingfees_htm.xml XML 5241
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-296972 | Film No.: 261111063
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)